Traumatic brain injury (TBI) is known as a “silent epidemic” (Simon et al., 2017). Annually, approximately 54 to 60 million people suffer from TBI worldwide (Bazarian et al., 2018). Survivors of TBI commonly live with neurocognitive deficits and physical disability and increased risk of neurodegenerative disease in the long term (Pattinson and Gill, 2018). Unfortunately, no drug has been approved in Phase III of clinical trials for treating TBI (Stocchetti et al., 2015) because of complex pathogenesis, such as burst reactive oxygen species, increased glutamate levels, destroyed blood–brain barrier (BBB), uncontrolled neuroinflammation, and obliterated synapse (Li et al., 2018; Ma et al., 2018; Ichkova et al., 2019). Thus, the consensus of multitarget intervention was formed as its therapeutic principle. The multitarget property and advantageous efficacy of traditional Chinese medicine (TCM) in TBI has attracted much attention (Xing et al., 2016) and has encouraged exploration of the integrative pathogenesis of TBI and the multitargeted pharmacomechanism of TCM through various omics technologies (Tu et al., 2014; Zheng, Wang, et al., 2017; Lipponen et al., 2018).

中文翻译：

---

基于 VISSA-PLS-DA 的代谢组学揭示了中医治疗创伤性脑损伤的多靶点机制

创伤性脑损伤 (TBI) 被称为“无声的流行病”（Simon 等，2017）。每年，全世界约有 54 至 6000 万人患有 TBI（Bazarian 等，2018）。从长远来看，TBI 的幸存者通常存在神经认知缺陷和身体残疾，并且患神经退行性疾病的风险增加（Pattinson 和 Gill，2018 年）。不幸的是，由于复杂的发病机制，例如活性氧爆发、谷氨酸水平升高、血脑屏障 (BBB) 破坏、不受控制神经炎症和突触消失（Li 等人，2018 年；Ma 等人，2018 年；Ichkova 等人，2019 年）。从而形成了多靶点干预的共识作为其治疗原则。